Erythropoietin (Epo) is a hematopoietic factor, which stimulates proliferation and differentiation of erythroid precursor cells. Epo also functions as a neuroprotective factor and protects neurons from ischemic damage. Recently a 17-mer peptide sequence (Epopeptide AB) in Epo (AEHCSLNENITVPDTKV) with a neuroprotective function was reported. In this study, we showed in vivo evidence that Epopeptide AB protected neurons from ischemic damage at similar dose compared to Epo. Epopeptide AB could not stimulate the proliferation of Epo-dependent growing murine myeloid Ep-FDC-P2 cells and also did not compete the proliferative function of Epo on these cells. Together with these results, Epopeptide AB did not transduce signals through direct binding to the known Epo receptor on hematopoietic cells but has neuroprotective activity against ischemia.
Introduction
Erythropoietin (Epo) is a specific factor for red blood cell formation. Epo is produced in the adult kidney and stimulates the growth and differentiation of erythroid precursor cells in bone marrow (Krantz 1991) . Epo is also produced independently in brain and it protects neurons from ischemic damage as reported in our previous study ). This finding promotes researches towards the development of Epo as a new clinical medicine for neuronal damage (Brines et al. 2000; Siren et al. 2001; Junk et al. 2002) . Administration of a large amount of Epo could protect neurons from ischemic damage (Brines et al. 2000) . However, this may cause the risk of unwanted effects linked to the overstimulation of erythropoiesis. Recombinant Epo should be produced in mammalian cells since glycosylation of Epo is essential for the stability of Epo in the blood flow (Yamaguchi et al. 1991) . However, production of recombinant proteins by animal cells is costly. Campana et al. described that Epopeptide AB, a partial peptide of Epo had neuroprotective activity without hematopoietic activity (Campana et al. 1998) . If this peptide is equally effective to ischemic damage compared to Epo, this peptide may become a promising substitute of Epo for the therapy against ischemic damage since this peptide is easy to be synthesized and has no hematopoietic activity. Whether Epopeptide AB has neuroprotective activity against ischemic damage in vivo was examined in this study.
Materials and methods

Synthesis of Epopeptide AB
Epopeptide AB was synthesized by Pioneer TM peptide synthesizer (Applied Biosystems) using the Fmoc method as described (Irie et al. 1998) . Purified Epopetide AB was verified by MALDI-TOF-MS, Voyager (Applied Biosystems).
Osmotic minipump implantation
Male Mongolian gerbils each weighing 70-80 g ($12 weeks of age) were anesthetized with 1.5% halothane in a 4:3 mixture of nitrous oxide and oxygen and placed in a stereotaxic apparatus. An osmotic minipump (Alza) filled with either Epopeptide AB or vehicle was implanted subcutaneously into the back of each animal, and a needle from the minipump was placed in the left ventricle.
Infusion of Epopeptide AB
Epopeptide AB was dissolved in a vehicle consisting of 0.01 M phosphate buffered saline (pH 7.5) and 0.1% BSA. Epopeptide AB at a dose of 4 (n = 8) or 20 (n = 8) ng day À1 was infused for 7 days into the lateral ventricle of each normothermic gerbil in which 3-min forbrain ischemia had been induced as described (Wen et al. 1995) ; control animals (one group with 3-min forbrain ischemia and one group of sham operated animals) received vehicle infusion (n = 8 in each group).
Occlusion of the common carotid arteries
Occlusion of the common carotid arteries was performed as described (Wen et al. 1995) . Shamoperated animals were treated in the same manner except that the common carotid arteries were not clamped.
Estimation of learning ability by passive avoidance task
Seven days after forbrain ischemia, the gerbils were trained in a conventional step-down passive avoidance apparatus that was divided into a safe platform and a chamber with a stainless-steel grid floor. Learning ability was estimated as described (Wen et al. 1995) .
Histopathological study of hippocampal CA1 region
One hour after the passive avoidance experiments, each animal was anesthetized with pentobarbital and the hippocampal CA1 region of each animal was examined histopathologically as described (Wen et al. 1995) .
Statistics
The effects of Epopeptide AB on response latency and CA1 neuronal density were evaluated by the two-tailed Mann-Whitney U test, which enabled us to compare the Epopeptide AB-treated group with corresponding ischemic control groups. All data were represented as mean ± SE.
Epo dependency of cell proliferation
Epo-dependent growing murine myeloid Ep-FDC-P2 cells were given from Snow Brand Milk Products Co., Ltd (Yamaguchi et al. 1991) . For the assay of Epo or Epopeptide AB dependency of cell proliferation, the cells were washed extensively with RPMI 1640 medium before assay. Cells at a density of 30,000 per well were seeded in 96-well microtiter plates in the presence of various concentrations of Epo or Epopeptide AB and cultured for 20 h. Viable cells were measured colorimetrically by the use of the cleavage of MTT (Mosmann 1983) .
Results
Protective effect of Epopeptide AB on ischemiainduced neuron death
The response latency in the step-down passive avoidance task, which is an index of learning ability, and CA1 neuronal density of sham-operated animals with vehicle infusion were 240 ± 10 s and 245 ± 5 cells mm À1 , respectively, while those of 3 min ischemic gerbils infused with vehicle alone were 125 ± 8 s and 138 ± 10 cells mm À1 , respectively. There were significant differences in response latency (U = 0, p < 0.01) and CA1 neuron density (U = 0, p < 0.01) between the two groups (Figure 1a, b) . In histological sections, CA1 region of 3-min ischemic gerbils exhibited a marked decline in viable neurons, when compared with the CA1 field of sham-operated animals Figure 1c, d) .
The continuous infusion of Epopeptide AB at a dose of 4 or 20 ng day À1 for 7 days into the lateral ventricle just after ischemia/reperfusion caused a significant prolongation in response latency time (Epopeptide AB vs. vehicle in ischemic girbils: U = 19.0, p < 0.05; U = 9.0, p < 0.01) (Figure 1a) . Subsequent histological examination revealed that treatment with Epopeptide AB at the dose of 4 or 20 ng day À1 rescued many ischemic neurons that were destined to degenerate without the treatment (Epopetide AB vs. vehicle in ischemic gerbils: U = 19.0, p < 0.05; U = 11.5, p < 0.01) (Figure 1b , e, and f). We previously described that Epo at a dose of approximately 50 ng day À1 for 7 days had similar effect when the infusion of Epo was started at 8 h before the ischemic insult ).
Epopeptide AB could not stimulate the growth of Ep-FDC-P2 cells
Epopeptide AB could not stimulate the growth of Epo-dependent growing myeloid Ep-FDC-P2 cells in the concentration range of 0.01-100 nM (Figure 2 ). Epo-dependent growth of Ep-FDC-P2 cells at the concentration of 0.5 nM was not inhibited by the addition of Epopetide AB in the concentration range of 0.5-250 nM, suggesting that at least Epopeptide AB do not bind directly to the known Epo receptor on this cell line at the similar affinity compared to Epo (Figure 3) . No binding of Epopeptide AB to soluble form of Epo receptor was also observed by surface resonance measurement using BIACORE (data not shown).
Discussion
Epo, which is produced by the fetal liver and by the adult kidney, is the primary stimulator of red blood cell formation. Erythropoietic stimulation was believed to be the sole physiological function of Epo, but we found that Epo produced in the central nervous system protected neurons from ischemic damage ). Campana et al. showed that Epopeptide AB, a 17-mer partial peptide of Epo, induced differentiation of both murine NS20Y and human SK-N-MC neuroblastoma cells and prevented death of the cells, but had no erythropoietic activity (Campana et al. 1998) . In this study we described that Epopeptide AB protected hipocammpal neurons from ischemic damage in vivo at the similar dose compared to Epo. Since Epo prevented place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery when Epo infusion was started just after occlusion (Sadamoto et al. 1998) , Epopeptide AB was infused just after ischemic treatment in this study. Epopeptide AB could not stimulate the proliferation of murine myeloid Ep-FDC-P2 cells whose growth is Epo-dependent, and did not inhibit the Epo-dependent growth of the cells, suggesting that Epopeptide AB could not bind to the known Epo receptor. Whether Epo protects neurons from ischemic damage through the known Epo receptor or not is controversial. Campana et al. described that anti-Epo receptor antibody blocked Epopeptide AB-induced neurite outgrowth in murine NS20Y cells (Campana et al. 1998 ). X-ray crystal analysis of the Epo-Epo receptor complex suggested that the C-terminal Thr-Lys-Val sequence of epopetide AB may interact with Epo receptor ( Syed et al. 1998 ), but the mutation of Lys to Ala in this sequence caused no change in specific bioactivity of Epo (Wen et al. 1994) , suggesting that the binding of Epopetide AB to the known Epo receptor is unlikely. Leist et al. described that carbamylated Epo did not bind to the known Epo receptor but conferred neuroprotection against stroke (Leist et al. 2004) , supporting the notion that other unknown receptor of Epo is involved in the neuroprotection signals of Epo. One possible mechanism is that Epopeptide AB binds to an unknown Epo receptor, which is involved in the heteromeric receptor complexes containing classical Epo receptor and indirectly activates the classical Epo receptor. Identification of a novel Epo receptor is expected. Very recently, Brines et al. suggested that Epo receptor and the common b receptor (bcR) subunit comprise a tissue-protective heteroreceptor . The bcR provides increased ligand-binding affinity to the receptor complex and is also the signal-transducing component common to the granulocyte-macrophage colony stimulating factor, interleukin-3 receptor, and interleukin-5 receptors. Further studies are needed to clarify whether Epopeptide AB binds either the bcR, the heteroreceptor complex of the bcR and Epo receptor, or an unknown receptor.
Epopeptide AB is easy to be synthesized and had in vivo neuroprotective activity against ischemic damage when continuously infused just after the ischemia/reperfusion without hematopoietic activity. So this peptide is a good medicinal candidate for the therapy of brain ischemia. Furthermore if a receptor of Epopeptide AB is identified, a new low molecular weight synthetic ligand for the receptor, which can pass through the blood brain barrier may be screened.
